Advances in Mitochondrial Medicine

  • Roberto Scatena
  • Patrizia Bottoni
  • Bruno Giardina

Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 942)

Table of contents

  1. Front Matter
    Pages i-xii
  2. Physiology and Structure of Mitochondria

    1. Front Matter
      Pages 1-1
    2. Sergio Papa, Pietro Luca Martino, Giuseppe Capitanio, Antonio Gaballo, Domenico De Rasmo, Anna Signorile et al.
      Pages 3-37
    3. Hongzhi Li, Danhui Liu, Jianxin Lu, Yidong Bai
      Pages 39-51
    4. Tito Calì, Denis Ottolini, Marisa Brini
      Pages 53-73
    5. Paolo Sarti, Marzia Arese, Elena Forte, Alessandro Giuffrè, Daniela Mastronicola
      Pages 75-92
    6. Jérome Estaquier, François Vallette, Jean-Luc Vayssiere, Bernard Mignotte
      Pages 157-183
  3. Mitochondria and Disease

    1. Front Matter
      Pages 185-185
    2. Josef Finsterer
      Pages 187-213
    3. Myrte Brands, Arthur J. Verhoeven, Mireille J. Serlie
      Pages 215-234
    4. Philip Newsholme, Celine Gaudel, Maurico Krause
      Pages 235-247
    5. Elinor J. Griffiths
      Pages 249-267
    6. Lezi E, Russell H. Swerdlow
      Pages 269-286
  4. Mitochondria, Aging and Pharmacotoxicological Aspects

    1. Front Matter
      Pages 309-309
    2. Hsin-Chen Lee, Yau-Huei Wei
      Pages 311-327
    3. Roberto Scatena
      Pages 329-346

About this book

Introduction

Mitochondria are far more than the “powerhouse” of the cell as they have classically been described. In fact, mitochondria biological activities have progressively expanded to include not only various bioenergetic processes but also important biosynthetic pathways, calcium homeostasis and thermogenesis, cell death by apoptosis, several different signal transduction pathways mainly related to redox control of gene expression and so on. This functional and structural complexity may undergo important derangements so to justify the definition of ‘mitochondrial medicine’, which should include all the clinical consequences of congenital or acquired mitochondrial dysfunctions. There are actually a growing number of studies which assign a significant pathogenic role to damaged mitochondria in different diseases: ischemia/reperfusion injury, neurodegenerative diseases, cancer with its dramatic sequelae (i.e, metastasis), metabolic syndrome, hyperlipidemias, just to mention a few of the most important pathologies. In this context, a further aspect that should not be disregarded is the interaction of pharmacological agents with mitochondria, not only in regard of the toxicological aspects but, above all, of the potential therapeutic applications. In fact, it is interesting to note that, while the properties of different so-called “mitoxicants” are well-known, the subtle linkages between drugs and mitochondria is still in need of a real pharmacological and therapeutic control at the clinical level. This lack of consideration can often lead to an underestimation of unwanted toxic effects but also of desirable therapeutic activities. A reevaluation of the potential clinical role of mitochondria could give a new light on some yet obscure aspects of human pathophysiology.

Keywords

Cancer Diabetes Mellitus Metabolic Diseases Neurodegenerative disease Pharmacology

Editors and affiliations

  • Roberto Scatena
    • 1
  • Patrizia Bottoni
    • 2
  • Bruno Giardina
    • 3
  1. 1.School of Medicine, Institute of Biochemistry and Clinical BCatholic UniversityRomeItaly
  2. 2.School of Medicine, Institute of Biochemistry and Clinical BCatholic UniversityRomeItaly
  3. 3.School of Medicine, Institute of Biochemistry and Clinical BCatholic UniversityRomeItaly

Bibliographic information

  • DOI https://doi.org/10.1007/978-94-007-2869-1
  • Copyright Information Springer Science+Business Media B.V. 2012
  • Publisher Name Springer, Dordrecht
  • eBook Packages Biomedical and Life Sciences
  • Print ISBN 978-94-007-2868-4
  • Online ISBN 978-94-007-2869-1
  • Series Print ISSN 0065-2598
  • About this book